Tramway Venture Partners — 2024 Investments

1 investments dated 2024 · listed companies and verified rows first · show all

Circular Genomicscirculargenomics.comin 𝕏Jan 2024SEC filingmedium confidence

Circular Genomics develops a proprietary platform using circular RNA biomarkers to enable early detection and understanding of neurological diseases through blood tests.

AI & Machine LearningBiotechDigital HealthMedical DevicesAlbuquerque, US

Alexander Hafez(Executive Officer, Director, Promoter)Nikolaos Mellios(Director, Promoter)

Board seatWaneta Tuttle· per SEC Form D · $15M raise · filed Jan 2024

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.